Notably, ARID1A has a mutually exclusive paralog subunit, ARID1B, which was identified as a major vulnerability in ARID1A-deficient cancer cell lines [10], suggesting that ARID1B is a therapeutic target in ARID1A-deficient cancers. This evidence concerns the gene ARID1B and cancer.